Chronic Inducible Urticaria

Chronic urticaria with identified triggering factor which is either physical, e.g., vibratory urticaria, or non-physical, e.g., aquagenic urticaria.

Also Known As:

Urticaria, Aquagenic; Aquagenic Urticarias; Chronic Inducible Urticarias; Inducible Urticaria, Chronic; Vibratory Urticarias; Aquagenic Urticaria; CIndU; Urticaria, Vibratory; Vibratory Urticaria

Networked: 94 relevant articles (10 outcomes, 14 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Chronic Urticaria
2.	Urticaria (Hives)
3.	Chronic Inducible Urticaria
4.	Hypersensitivity (Allergy)
5.	Cold Urticaria

Experts

1.	Maurer, Marcus: 13 articles (01/2022 - 01/2014)
2.	Altrichter, Sabine: 5 articles (01/2022 - 11/2019)
3.	Metcalfe, Dean D: 5 articles (01/2021 - 02/2016)
4.	Olivera, Ana: 5 articles (01/2021 - 02/2016)
5.	Maurer, M: 3 articles (01/2021 - 01/2016)
6.	Church, Martin K: 3 articles (12/2019 - 01/2014)
7.	Metz, Martin: 3 articles (01/2018 - 01/2014)
8.	Giménez-Arnau, Ana M: 2 articles (02/2022 - 11/2018)
9.	Ben-Shoshan, Moshe: 2 articles (01/2022 - 10/2021)
10.	Gabrielli, Sofianne: 2 articles (01/2022 - 10/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Chronic Inducible Urticaria:

1.	Omalizumab (Xolair)FDA Link 01/01/2021 - "Omalizumab is highly effective in patients with difficult-to-treat CSU, CIndU, or both. " 01/01/2014 - "When starting with 150mg omalizumab 4 weekly, only 2/15 CSU and 7/17 CindU patients required updosing to achieve complete remission. " 01/01/2014 - "Omalizumab treatment led to complete remission in 83% of CSU and 70% of CindU patients. " 12/01/2022 - "There was no significant difference in the efficacy of omalizumab in the treatment of CSU and CIndU (OR -0.83, 95% CI [0.84, 2.21], P > 0.05). " 07/11/2022 - "Omalizumab may be slightly more effective against CSU than against CIndU. "
2.	Histamine Antagonists (Antihistamines)IBA 08/01/2019 - "However, CIndU seem to be more resistant to standard doses of H1 antihistamines (AHs) and higher doses of AHs are required for symptom control. " 01/01/2014 - "We report the case of an adolescent boy with aquagenic urticaria unresponsive to oral antihistamine therapy. " 12/01/2019 - "CIndU patients were younger, showed less angioedema, and had a better response to antihistamines. " 09/01/2022 - "According to the 2016 consensus recommendations on chronic inducible urticarias, all the participants perform at least 1 of the available provocation tests and 84.2%, 77.8%, and 88.9% prescribe on-label use of second generation anti-H1 antihistamines (2GAH1) as a first line treatment, updosed 2GAH1 as a second line treatment, and omalizumab as a third line treatment, respectively. " 07/18/2022 - "Omalizumab as a treatment option for antihistamine-refractory aquagenic urticaria."
3.	Cholinergic Agents (Cholinergics)IBA 01/01/2023 - "In chronic inducible urticaria, specific triggers may include dermatographism, cholinergic (heat), cold, exercise, delayed pressure, and solar. " 01/01/2019 - "We enrolled 127 patients (59.1% females), ranging in age from 15 to 83 years, 69.3% had CSU alone, 26.8% had CSU and CIndU, and 3.9% had only CIndU (30.8% delayed pressure, 35.9% dermographic, 15.3% cholinergic, 12.8% cold, 5.1% aquagenic). " 01/01/2013 - "Cold, cholinergic and aquagenic urticaria in children: presentation of three cases and review of the literature." 09/01/1983 - "It is an entity to be distinguished from cholinergic and aquagenic urticaria. " 09/01/1981 - "Aquagenic urticaria: evidence of cholinergic and histaminergic basis."
4.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/01/2020 - "A role for the adhesion G-protein coupled receptor ADGRE2 or EMR2 in mechanosensing was revealed by the finding of a missense substitution (p.C492Y) associated with familial vibratory urticaria. " 01/01/2018 - "This includes the Mas-related G protein-coupled receptor X2, which might contribute to reactions to diverse antimicrobials and polybasic compounds, and the adhesion G protein-coupled receptor E2, variants of which are associated with familial vibratory urticaria and are activated by mechanical vibration. " 01/01/2017 - "EMR2/ADGRE2 is a human myeloid-restricted adhesion G protein-coupled receptor critically implicated in vibratory urticaria, a rare type of allergy caused by vibration-induced mast cell activation. " 01/01/2021 - "Herein, we summarize recent advances in understanding the roles of mast cells in health and disease, partly through the study of emerging non-IgE receptors such as the Mas-related G protein-coupled receptor X2, implicated in pseudo-allergic reactions as well as in innate defense and neuronal sensing; the mechano-sensing adhesion G protein-coupled receptor E2, variants of which are associated with familial vibratory urticaria; and purinergic receptors, which orchestrate tissue damage responses similarly to the IL-33 receptor. "
5.	IgE Receptors (Fc epsilon RI)IBA 01/01/2022 - "IgE receptor responsiveness of basophils in chronic inducible urticaria." 02/01/2022 - "IgE and high-affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance." 01/01/2022 - "Basophil responsiveness via high-affinity IgE receptor (FcϵRI) stimulation with anti-IgE or anti-FcϵRI antibody in patients with CIndU was equivalent to that in HCs, and higher than that in patients with CSU. " 02/01/2022 - "IgE and high-affinity IgE receptor (FcεRI) expression on basophils have been scarcely explored in patients with chronic inducible urticaria (CIndU). " 01/01/2021 - "Herein, we summarize recent advances in understanding the roles of mast cells in health and disease, partly through the study of emerging non-IgE receptors such as the Mas-related G protein-coupled receptor X2, implicated in pseudo-allergic reactions as well as in innate defense and neuronal sensing; the mechano-sensing adhesion G protein-coupled receptor E2, variants of which are associated with familial vibratory urticaria; and purinergic receptors, which orchestrate tissue damage responses similarly to the IL-33 receptor. "
6.	anti-IgE antibodiesIBA 01/01/2022 - "Basophil responsiveness via high-affinity IgE receptor (FcϵRI) stimulation with anti-IgE or anti-FcϵRI antibody in patients with CIndU was equivalent to that in HCs, and higher than that in patients with CSU. " 02/01/2022 - "Although additional studies would be welcome, our work highlights the relevance of FcεRI receptor regulation in CIndU supporting autoimmune basophil and mast cell activation and may be a biomarker for response to anti-IgE therapy." 02/01/2022 - "The relationship of both parameters with the response to antihistamine and anti-IgE (omalizumab) treatment was considered in a subsample of CIndU patients. "
7.	Biomarkers (Surrogate Marker)IBA 02/01/2022 - "Although additional studies would be welcome, our work highlights the relevance of FcεRI receptor regulation in CIndU supporting autoimmune basophil and mast cell activation and may be a biomarker for response to anti-IgE therapy."
8.	Purinergic Receptors (Receptors, Purine)IBA 01/01/2021 - "Herein, we summarize recent advances in understanding the roles of mast cells in health and disease, partly through the study of emerging non-IgE receptors such as the Mas-related G protein-coupled receptor X2, implicated in pseudo-allergic reactions as well as in innate defense and neuronal sensing; the mechano-sensing adhesion G protein-coupled receptor E2, variants of which are associated with familial vibratory urticaria; and purinergic receptors, which orchestrate tissue damage responses similarly to the IL-33 receptor. "
9.	Interleukin-33IBA 01/01/2021 - "Herein, we summarize recent advances in understanding the roles of mast cells in health and disease, partly through the study of emerging non-IgE receptors such as the Mas-related G protein-coupled receptor X2, implicated in pseudo-allergic reactions as well as in innate defense and neuronal sensing; the mechano-sensing adhesion G protein-coupled receptor E2, variants of which are associated with familial vibratory urticaria; and purinergic receptors, which orchestrate tissue damage responses similarly to the IL-33 receptor. "
10.	SaltsIBA 12/01/2022 - "We present the first case of a localized salt-dependent aquagenic urticaria confirmed by a challenge test. " 01/01/2022 - "Salt-Dependent Aquagenic Urticaria, Challenge Test, and Histological Features: Case Report." 01/01/2018 - "Our case supports the existence of a distinct salt-dependent subtype of aquagenic urticaria (SDAU), which seems to be triggered mostly by sea bathing, affects young women and has a characteristic localization on the inferior facial contours and neck. " 01/01/2018 - "Salt-dependent aquagenic urticaria in children: Report of two cases." 12/01/2015 - "[Localized salt-dependent aquagenic urticaria: A case report]."

Therapies and Procedures

1.	Injections 01/01/2014 - "Clinical experience from more than 1250 injections in 51 patients over four years indicates that omalizumab is a rapidly acting, highly effective and safe drug in CSU and CindU patients. "
2.	Therapeutics 11/01/2018 - "Patients with CSU-CIndU required more frequent therapy after 5 years and higher doses of 2nd-generation H1-antihistamines. " 01/01/2014 - "To our knowledge, this is the first report showing the use of topical therapy alone to treat aquagenic urticaria in a child. " 01/01/2018 - "A strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU. " 01/01/2014 - "We report the case of an adolescent boy with aquagenic urticaria unresponsive to oral antihistamine therapy. " 02/01/2022 - "Although additional studies would be welcome, our work highlights the relevance of FcεRI receptor regulation in CIndU supporting autoimmune basophil and mast cell activation and may be a biomarker for response to anti-IgE therapy."
3.	Retreatment 03/01/2014 - "Participants included 25 consecutive patients (aged 18-74 years; 18 women) with chronic spontaneous urticaria, chronic inducible urticaria, or both who showed complete response to omalizumab treatment, experienced relapse after discontinuation of treatment, and received retreatment with omalizumab. "
4.	Traction 01/01/2017 - "Follicular Traction Urticaria: A New Form of Chronic Inducible Urticaria?"
5.	Thyroidectomy 12/01/2011 - "Aquagenic urticaria and syncope associated with occult papillary thyroid carcinoma and improvement after total thyroidectomy."